Novo Nordisk Stock Falls As 2026 Outlook Signals Pricing Pressure, Slowing Sales

Novo Nordisk A/S (NYSE:NVO) stock is trading lower on Tuesday after the weight-loss drug maker released its 2026 full-year sales and operating profit outlook.2026 OutlookNovo Nordisk expects reported 2026 sales and operating profit to benefit from a $4.2 billion reversal of 340B Drug Pricing Program in the U.S. In 2025, $400 million was excluded.Excluding this one-time item, the mid-point of sales and operating profit growth guidance for 2026, both at CER, would be -1% and 11%, respectively.Adjusted sales g ...